company? Let’s change
that.
Pulse Analytics builds business intelligence tools that help decision-makers in oncology and other specialty therapeutic areas reduce access barriers and restrictions in the healthcare industry. Pharma market access teams utilize our tools to understand the complex connections, policies, and key influencers at healthcare organizations to deliver targeted insights and support their customer engagement strategies. We go above traditional data platforms by operating in a highly specialized space and partnering with industry experts allowing our tools to provide tailored experiences that meet the unique needs and challenges of our clients.
EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.
We lead the global clinical trial performance improvement market by efficiently managing the patient experience through highly-personalized patient-centric services, unrivaled processes, and our team of professional experts. We streamline communication and coordination among clinical trial patients, sites, and stakeholders. We develop mutually beneficial, long-term relationships with clients and vendors who share our dedication and vision to humanize the patient experience.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. We hire the most brilliant minds because inventing for life depends on our work. Here, you'll find rewarding opportunities, diverse experiences, and an unwavering commitment to ethics and integrity. You'll collaborate with talented colleagues who share your sense of purpose. Our company will empower you to innovate, explore, and develop your full potential in our possibility-rich environment. Our team is constantly evolving, so if you are among the intellectually curious, join us—and start making your impact today.
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.